Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study.

OBJECTIVE

To explore the influence of bevacizumab combined with chemoradiotherapy on VEGF, bFGF, and Let-7 in patients with non-small cell lung cancer (NSCLC), and to analyze the factors affecting its efficacy.

METHODS

Totally 150 patients with non-small cell lung cancer (NSCLC) treated in our hospital from November 2018 to November 2023 were retrospectively analyzed. The serum levels of VEGF, bFGF, and Let-7 were collected and compared. Patients were divided into good efficacy and poor efficacy groups based on short-term efficacy, and logistic regression analysis was used to analyze the factors affecting efficacy.

RESULTS

Before treatment, there was no significant difference in the levels of VEGF, bFGF, and Let-7 between the two groups (P>0.05). After treatment, the levels of VEGF, bFGF, and Let-7 in both groups improved compared to before treatment, and compared with the control group, the study group had lower levels of VEGF and bFGF, and higher levels of Let-7, with statistically significant differences (all P<0.05). Multifactorial logistic regression analysis revealed that the course of disease, tumor diameter, and treatment regimen were independent factors influencing the therapeutic efficacy of NSCLC (all P<0.05).

CONCLUSION

For patients with NSCLC, the treatment regimen of bevacizumab combined with chemoradiotherapy can achieve better efficacy, with a higher objective response rate, effectively reduce the level of vascular endothelial growth factor, increase Let-7 level, and ensure safety. In addition, disease course, tumor diameter, and treatment regimen are independent factors affecting the efficacy of NSCLC. Therefore, these factors should be comprehensively considered when formulating treatment plans to ensure the best therapeutic effect.